6,47 $
3,85 %
Nasdaq, Fr, 01.03.2024
ISIN
US41015N1063
Symbol
HJLI
Berichte

Hancock Jaffe Laboratories, Inc. Aktie News

Neutral
Accesswire
mehr als 2 Jahre alt
Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories IRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, today announced that R...
Neutral
Accesswire
mehr als 2 Jahre alt
Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ET IRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today announced that Hancock Jaffe management will host a corporate update conference call with a li...
Positiv
Seeking Alpha
mehr als 2 Jahre alt
Hancock Jaffe Laboratories develops nature-mimetic bioprosthetics for patients with debilitating cardiovascular diseases. The Company got IDE approval in April 2021 to begin a pivotal trial of VenoValve in the U.S.
Neutral
Accesswire
mehr als 2 Jahre alt
IRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered into a definitive agreement with a fund managed by Perceptive Advisors, a leading life sciences investment firm, to purchase $20 million of its common stock and pre-funded warrants in a register...
Neutral
Accesswire
mehr als 2 Jahre alt
Two-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectively Patients with venous ulcers who experienced dramatic ulcer healing had no venous ulcer recurrences No safety issues occurred during the one-year reporting period following the study completion IRVINE, CA / ACCESSWIRE / August 19, 2021 / Hancock Jaffe Laboratories, I...
Positiv
Pulse2
mehr als 2 Jahre alt
The stock price of Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) increased by over 35% pre-market. This is why it happened.
Neutral
Accesswire
mehr als 2 Jahre alt
- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions - Company preparing to begin SAVVE U.S. pivotal trial for VenoValve - VenoValve is a potential treatment for approximately 2.4 million U.S. patients that suffer from severe Chronic Venous Insufficiency in the deep veins of their l...
Neutral
Accesswire
mehr als 2 Jahre alt
Live webcast on Tuesday, July 13th at 1:00 PM ET IRVINE, CA / ACCESSWIRE / July 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today announced that Robert Berman, CEO of Hancock Jaffe will present at the Ladenburg Thalmann 2021 Healthcare Conference on Tuesday, July 13, 2021 at...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen